INBX Soars 81% Post-Study; FEMY, CING, CYH Pop After Hours

Biotech stocks led the after-hours charge on Thursday, with Inhibrx Biosciences (INBX) skyrocketing over 81% on positive Phase 2 trial results in chondrosarcoma. Femasys (FEMY), Cingulate (CING), and Community Health Systems (CYH) also posted notable gains, driven by clinical milestones and upbeat earnings. Here's a look at the top post-market movers.Shares of Inhibrx Biosciences Inc. (INBX) surged over 81% at $51.52 in after-hours trading, propelled by positive topline results from its registrational Chon ...